2023 No. 2

2023 No.2

Theme Issue: The Short-term and Long-term Objectives of Traditional Chinese Medicines again Liver Fibrosis

Executive Chief Editor: LI Xiuhui

Beijing YouAn Hospital of Capital Medical University

Cover Content

Previous Issue | Next Issue

Select articles

Display Method:

Editorial

Advances in the experimental research on traditional Chinese medicine against liver fibrosis

Xiaofei SHANG, Xiuhui LI

2023, 39(2): 249-259. DOI: 10.3969/j.issn.1001-5256.2023.02.001

Abstract(1492)

HTML (586)

PDF (2025KB)(301)

Abstract:
Liver fibrosis is the common pathological process of chronic liver diseases caused by various etiologies such as viral hepatitis and alcoholism, and it can progress to liver cirrhosis and even liver cancer and seriously threatens human health. Traditional Chinese medicine (TCM) has the characteristi...

Discussions by Experts

Advances and thoughts in traditional Chinese medicine diagnosis and treatment of chronic hepatitis B-related liver fibrosis

Huanming XIAO, Meijie SHI, Yubao XIE, Xiaoling CHI

2023, 39(2): 260-266. DOI: 10.3969/j.issn.1001-5256.2023.02.002

Abstract(1128)

HTML (412)

PDF (1896KB)(157)

Abstract:
Liver fibrosis is a necessary intermediate process from the progression of chronic hepatitis B to liver cirrhosis and liver cancer. In recent years, breakthroughs have been made in the research on traditional Chinese medicine (TCM) for the prevention and treatment of chronic hepatitis B liver fibros...

Advantages and characteristics of traditional Chinese medicine in the treatment of liver fibrosis

Junhong LIU, Xinyu LI, Miaolei WANG, Boya FU, Linman LI, Hui FANG

2023, 39(2): 267-272. DOI: 10.3969/j.issn.1001-5256.2023.02.003

Abstract(1638)

HTML (428)

PDF (2107KB)(170)

Abstract:
Hepatic fibrosis (HF) is the common pathological process of various chronic liver diseases and is associated with the progression of liver diseases, and it is also a key factor affecting the outcome of liver diseases and the risk of hepatocellular carcinoma (HCC). The early process of HF is reversib...

Blocking and reversing liver fibrosis with traditional Chinese medicine compound prescriptions: Beyond the known frontiers

Zhaofang BAI, Xiaoyan ZHAN, Guiji LYU, Yongping YANG

2023, 39(2): 273-277. DOI: 10.3969/j.issn.1001-5256.2023.02.004

Abstract(1413)

HTML (584)

PDF (1874KB)(190)

Abstract:
Liver fibrosis is the inevitable course for the progression of chronic hepatitis B to liver cirrhosis and is also the most important risk factor for hepatocarcinogenesis, and therefore, blocking and reversing liver fibrosis is an important strategy to effectively reduce the development of chronic he...

Association between liver fibrosis and gut microbiota based on "harmonizing liver and spleen"

Yunxiao LIU, Jing DOU, Xiaozhong WANG

2023, 39(2): 278-283. DOI: 10.3969/j.issn.1001-5256.2023.02.005

Abstract(1038)

HTML (477)

PDF (1890KB)(119)

Abstract:
Liver fibrosis is the leading cause of the morbidity and mortality of liver diseases worldwide and has become one of the key issues in the research on chronic liver diseases among domestic and foreign scholars. An increasing amount of evidence has shown that gut microbiota dysbiosis plays a crucial ...

Advances in integrated traditional Chinese and Western medicine diagnosis and treatment of hepatic fibrosis

Xueping ZHANG, Xiaofei SHANG, Xiuhui LI

2023, 39(2): 284-289. DOI: 10.3969/j.issn.1001-5256.2023.02.006

Abstract(1175)

HTML (467)

PDF (1888KB)(168)

Abstract:
Hepatic fibrosis (HF) is a key stage in the progression of chronic hepatitis to liver cirrhosis and even liver cancer, and it is a dynamic and reversible pathological change. Studies have shown that integrated traditional Chinese and Western medicine therapy has a good therapeutic effect on HF and c...

Guideline

Chinese guidelines for the diagnosis and treatment of pancrestic cystic neoplasm(2022)

National Clinical Research Center for Digestive Diseases (Shanghai), Professional Committee of Pancreatic Disease, Chinese Medical Doctor Association

2023, 39(2): 290-298. DOI: 10.3969/j.issn.1001-5256.2023.02.007

Abstract(2688)

HTML (1102)

PDF (2948KB)(866)

Abstract:

Original Article_Viral Hepatitis

Predictive factors for functional cure after sequential therapy with nucleos(t)ide analogues and pegylated interferon alfa-2b in treatment of chronic hepatitis B

Haiyang ZANG, Weina LI, Shousheng LIU, Yong ZHOU, Yongning XIN

2023, 39(2): 299-306. DOI: 10.3969/j.issn.1001-5256.2023.02.008

Abstract(1043)

HTML (816)

PDF (2089KB)(112)

Abstract:
Objective To investigate the independent predictive factors for functional cure after long-term nucleos(t)ide analogue (NUC) antiviral therapy followed by pegylated interferon α-2b therapy in chronic hepatitis B (CHB) patients. Methods A total of 162 CHB patients who were admitted to several hospita...

Value of indocyanine green clearance test combined with total bilirubin actual resident rate in evaluating the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure after artificial liver support system therapy

Honglian DU, Ye LI, Bo WANG, Linkun MA, Tiantian HU, Yunjian SHENG, Wen CHEN, Gang WU, Cunliang DENG

2023, 39(2): 307-315. DOI: 10.3969/j.issn.1001-5256.2023.02.009

Abstract(770)

HTML (433)

PDF (2120KB)(74)

Abstract:
Objective To establish a new model of indocyanine green (ICG) clearance test combined with total bilirubin actual resident rate (TBARR) for predicting the short-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) treated with artificial liver support s...

Effect of cyclin D1 on HBV transcription and replication

Siwen PENG, Guiwen GUAN, Ting ZHANG, Fengmin LU, Jia LIU, Xiangmei CHEN

2023, 39(2): 316-324. DOI: 10.3969/j.issn.1001-5256.2023.02.010

Abstract(770)

HTML (484)

PDF (5284KB)(81)

Abstract:
Objective To investigate the effect of cyclin D1 (with CCND1 as the gene name) on HBV replication and its potential mechanism. Methods With reference to GSE84044 dataset, the Spearman's rank correlation analysis was used to investigate the correlation between the expression levels of genes in liver ...

Original Article_Autoimmune Liver Disease

Prevalence of primary biliary cholangitis in the Chinese general population and its influencing factors: A systematic review

Zhicheng LIU, Zilong WANG, Jiarui ZHENG, Yandi XIE, Guangjun SONG, Bo FENG

2023, 39(2): 325-332. DOI: 10.3969/j.issn.1001-5256.2023.02.011

Abstract(1435)

HTML (1051)

PDF (2441KB)(195)

Abstract:
Objective To systematically review the epidemiological studies on primary biliary cholangitis (PBC), and to investigate the prevalence rate of PBC in the Chinese general population and its influencing factors. Methods PubMed, Embase, The Cochrane Library, CNKI, and Wanfang Data were searched for art...

Efficacy of transjugular intrahepatic portosystemic shunt in treatment of primary biliary cholangitis with portal hypertension

Yaru TONG, Xiaochun YIN, Wei ZHANG, Chang SUN, Ming ZHANG, Yuzheng ZHUGE

2023, 39(2): 333-338. DOI: 10.3969/j.issn.1001-5256.2023.02.012

Abstract(816)

HTML (372)

PDF (2133KB)(79)

Abstract:
Objective To investigate the long-term efficacy of transjugular intrahepatic portosystemic shunt (TIPS) in the treatment of primary biliary cholangitis (PBC) with portal hypertension. Methods A retrospective analysis was performed for 102 patients who received TIPS in Affiliated Drum Tower Hospital ...

Original Article_Liver Fibrosis and Liver Cirrhosis

Value of blood ammonia and cholinesterase in the early diagnosis of liver cirrhosis with minimal hepatic encephalopathy

Xuhong YANG, Yong YANG, Minglei WANG, Wenxiao LIU, Wanlong MA, Minxing WANG, Xiangchun DING, Xiaodong WANG

2023, 39(2): 339-344. DOI: 10.3969/j.issn.1001-5256.2023.02.013

Abstract(983)

HTML (400)

PDF (2173KB)(76)

Abstract:
Objective To investigate the value of serum markers in the early diagnosis of liver cirrhosis with minimal hepatic encephalopathy (MHE). Methods A prospective analysis was performed for 81 patients who were hospitalized and treated in General Hospital of Ningxia Medical University from April 2020 to...

Effect of traditional Chinese medicine on portal vein thrombosis in patients with liver cirrhosis and its medication characteristics

Yanan GUO, Hongtu GU, Changqing ZHAO, Yongping MU, Jili YUAN, Feng XING, Yanyan TAO, Jing LYU, Chenghai LIU

2023, 39(2): 345-351. DOI: 10.3969/j.issn.1001-5256.2023.02.014

Abstract(1135)

HTML (468)

PDF (2209KB)(96)

Abstract:
Objective To investigate the therapeutic effect of traditional Chinese medicine (TCM) on portal vein thrombosis (PVT) in patients with liver cirrhosis and its medication characteristics. Methods A retrospective analysis was performed for 89 patients with liver cirrhosis and PVT who were hospitalized...

Distribution of traditional Chinese medicine syndrome types and elements in liver cirrhosis patients with dysplastic nodules: An analysis of 138 cases

Xiaoxiao YAO, Yaokun HAO, Zhun XIAO, Lan ZHANG, Suping MA, Wenxia ZHAO

2023, 39(2): 352-358. DOI: 10.3969/j.issn.1001-5256.2023.02.015

Abstract(883)

HTML (502)

PDF (2714KB)(53)

Abstract:
Objective To investigate the distribution of traditional Chinese medicine (TCM) syndrome types and elements in liver cirrhosis patients with dysplastic nodules (DN), and to provide a basis for exploring the connotation and pattern of TCM syndrome types of DN in liver cirrhosis. Methods A total of 13...

Original Article_Other Liver Disease

Influencing factors for acute kidney injury in acute liver failure and establishment of a predictive model

Mengyue SHANG, Yalin TONG, Yongzhong CHEN, Jie BAO

2023, 39(2): 359-364. DOI: 10.3969/j.issn.1001-5256.2023.02.016

Abstract(929)

HTML (457)

PDF (2062KB)(83)

Abstract:
Objective To investigate the predictive factors for acute kidney injury (AKI) in patients with acute liver failure (ALF), and to establish a new predictive model. Methods Clinical data were collected from 253 patients who were diagnosed with ALF in The First Affiliated Hospital of Zhengzhou Universi...

Clinical features of myeloproliferative neoplasms with portal hypertension as the main manifestation

Lijuan FENG, Yan WANG, Min WANG, Guanhua ZHANG, Fuliang HE, Xinyan ZHAO, Yu WANG

2023, 39(2): 365-369. DOI: 10.3969/j.issn.1001-5256.2023.02.017

Abstract(827)

HTML (377)

PDF (2315KB)(85)

Abstract:
Objective To investigate the clinical features, liver histological features, and diagnostic and treatment methods for patients with myeloproliferative neoplasms (MPN) with portal hypertension as the main manifestation. Methods A retrospective analysis was performed for related data of the patients w...

Original Article_Biliary Disease

Value of endoscopic ultrasonography in the diagnosis of muddy stones of the common bile duct

Xuecai WANG, Qifang ZHANG, Xiaoyan LI, Wei PAN, Liangqing YANG, Hailian ZHANG

2023, 39(2): 370-375. DOI: 10.3969/j.issn.1001-5256.2023.02.018

Abstract(963)

HTML (502)

PDF (2729KB)(64)

Abstract:
Objective To investigate whether endoscopic ultrasonography (EUS) can be an alternative method for diagnostic endoscopic retrograde cholangiopancreatography (ERCP) by comparing the ability of EUS versus CT and transabdominal ultrasonography (TUS) in the diagnosis of muddy stones of the common bile d...

Effect of Dahuang Lingxian prescription on the scf/c-kit signaling pathway in gallbladder interstitial cells of Cajal in a guinea pig model of cholesterol gallstone

Lijun XIAO, Yirong GAN, Chunli LIU, Chengji LI, Wen YANG, Jiaoan PANG, Jinhao TENG, Yuan YU

2023, 39(2): 376-382. DOI: 10.3969/j.issn.1001-5256.2023.02.019

Abstract(782)

HTML (431)

PDF (3342KB)(95)

Abstract:
Objective To investigate the expression levels of scf and c-kit under the regulation of Dahuang Lingxian prescription and the possible mechanism of its effect on gallbladder dynamics, and to provide a theoretical basis for Dahuang Lingxian prescription in preventing the development and recurrence of...

Case Report

A case of idiopathic portal hypertension with psoriasis

Hui ZHOU, Bin NIU, Xiaoying ZHANG, Wei CHEN, Yuqiang MI, Ping LI

2023, 39(2): 383-386. DOI: 10.3969/j.issn.1001-5256.2023.02.020

Abstract(785)

HTML (424)

PDF (3689KB)(82)

Abstract:

Report and genetic analysis of autoimmune liver diseases between mother and daughter

Yujie QIN, Wenxiu ZHOU, Xingnian ZHOU, Mingliang CHENG, Hong LI

2023, 39(2): 387-391. DOI: 10.3969/j.issn.1001-5256.2023.02.021

Abstract(1055)

HTML (488)

PDF (3297KB)(75)

Abstract:

Klebsiella pneumoniae liver abscess in a patient with selective IgA deficiency

Rui DING, Ligai LIU, Ying FAN, Yanbin WANG, Wen XIE

2023, 39(2): 392-396. DOI: 10.3969/j.issn.1001-5256.2023.02.022

Abstract(781)

HTML (370)

PDF (1941KB)(74)

Abstract:

A case report of successful diagnosis and treatment of hepatic sinusoidal obstruction syndrome

Wenqian GENG, Hao ZHU, Xin YANG, Wanyu LI, Fang XU, Yanjun CAI, Pujun GAO

2023, 39(2): 397-400. DOI: 10.3969/j.issn.1001-5256.2023.02.023

Abstract(958)

HTML (398)

PDF (2418KB)(108)

Abstract:

Review

Association of dietary behavior with nonalcoholic fatty liver disease

Yifu YUAN, Qin CAO, Yuanye JIANG

2023, 39(2): 401-407. DOI: 10.3969/j.issn.1001-5256.2023.02.024

Abstract(769)

HTML (588)

PDF (1905KB)(114)

Abstract:
The prevalence rate of nonalcoholic fatty liver disease (NAFLD) is increasing year by year, which poses a heavy burden on global public health. The pathogenesis of NAFLD is closely associated with the factors including obesity, insulin resistance, and diet, among which diet is the core and cornersto...

Advances in the application of elastography in noninvasive diagnosis of liver fibrosis in nonalcoholic fatty liver disease

Meng LU, Mingjie WANG, Li CHEN

2023, 39(2): 408-412. DOI: 10.3969/j.issn.1001-5256.2023.02.025

Abstract(884)

HTML (677)

PDF (1876KB)(105)

Abstract:
Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease, and liver fibrosis is closely associated with the prognosis in NAFLD; therefore, accurate assessment of liver fibrosis is of great importance. Liver biopsy is the gold standard for the diagnosis of NAFLD, but ...

Research advances in nanomedicine in treatment of liver fibrosis

Jialing GUO, Hui LI, Zijian ZENG, Yujing TAO, Haijian DONG

2023, 39(2): 413-418. DOI: 10.3969/j.issn.1001-5256.2023.02.026

Abstract(1137)

HTML (431)

PDF (1897KB)(128)

Abstract:
Liver fibrosis (LF) is a pathological process of hepatic stellate cell (HSC) activation and excessive deposition of extracellular matrix caused by chronic liver injury and inflammation. HSC activation is the core mechanism of LF, and inhibiting HSC activation is the key to promoting the reversal of ...

Association between liver sinusoidal endothelial cells and liver fibrosis

Weiming DAI, Lungen LU, Xiaobo CAI

2023, 39(2): 419-423. DOI: 10.3969/j.issn.1001-5256.2023.02.027

Abstract(1280)

HTML (983)

PDF (2289KB)(140)

Abstract:
Liver sinusoidal endothelial cells (LSECs) are crucial to the maintenance of hepatic homeostasis under physiologic conditions, while under the conditions of pathological liver damage, LSEC can respond to the damage by changing their structure through the process called capillarization, thereby aggra...

Advances in minimally invasive treatment of upper gastrointestinal bleeding in liver cirrhosis

Min XU, Yu NI, Rui ZHANG, Xiaobing WANG, Yuan HUANG

2023, 39(2): 424-431. DOI: 10.3969/j.issn.1001-5256.2023.02.028

Abstract(933)

HTML (407)

PDF (2072KB)(92)

Abstract:
Liver cirrhosis is a common chronic liver disease in clinical practice, and the main causes of this disease include virus, alcohol, and immunity. Patients may experience a variety of complications in the late stage of liver cirrhosis, including upper gastrointestinal bleeding, hepatic encephalopathy...

Biological connotation of "phlegm-turbidity" theory in hepatocellular carcinoma microenvironment based on abnormal lipid metabolism

Fangming YANG, Zhun XIAO, Xiaoqi CHEN, Chuanlei ZHANG, Xinju CHEN, Suping MA, Wenxia ZHAO

2023, 39(2): 432-438. DOI: 10.3969/j.issn.1001-5256.2023.02.029

Abstract(966)

HTML (533)

PDF (3964KB)(66)

Abstract:
There is still a lack of effective strategies for the prevention and treatment of liver cancer, and a deep understanding of its pathogenesis may help to develop new treatment methods. Due to the abnormal changes of lipid metabolism in the development and progression of liver cancer, such process is ...

From viral hepatitis to hepatocellular carcinoma: The role of exosomal microRNAs

Yuanpeng MAO, Zhe YU, Aqian SONG, Hongshan WEI

2023, 39(2): 439-443. DOI: 10.3969/j.issn.1001-5256.2023.02.030

Abstract(946)

HTML (396)

PDF (2163KB)(115)

Abstract:
Exosomes are nano-sized phospholipid bilayer vesicles containing abundant and complex biomolecules, such as DNA, mRNAs, microRNAs (miRNAs), lipids, and proteins. Exosomes can be secreted and ingested by most types of cells to transfer information through intercellular transport. After uptake by reci...

Research advances in myosteatosis in chronic liver diseases

Jintao SUN, Fengxia LI

2023, 39(2): 444-449. DOI: 10.3969/j.issn.1001-5256.2023.02.031

Abstract(910)

HTML (526)

PDF (2465KB)(78)

Abstract:
Myosteatosis is the main manifestation of malnutrition and is a common complication of chronic liver diseases, with a negative impact on the progression and prognosis of liver diseases. There is no gold standard for the diagnosis of myosteatosis, and CT is a commonly used diagnostic method. Myosteat...

Research advances in congenital extrahepatic portosystemic shunt

Ying WANG, Shengrun XU, Di YU, Jinhui YANG, Jiang CHANG

2023, 39(2): 450-456. DOI: 10.3969/j.issn.1001-5256.2023.02.032

Abstract(1108)

HTML (734)

PDF (2399KB)(100)

Abstract:
Congenital extrahepatic portosystemic shunt (CEPS) is also called Abernethy malformation, with the manifestation of congenital abnormal anastomosis between the portal vein and the inferior vena cava. CEPS is extremely rare in clinical practice and has diverse clinical symptoms, which often leads to ...

Advances in the application of three-dimensional visualization technique in hepatic alveolar echinococcosis

Dong ZHANG, Zhixin WANG, Qian ZHAO, Xiaoxia SU, Kai XU, Mingming DONG, Wei LI, Lizhao HOU, Haining FAN, Haijiu WANG

2023, 39(2): 457-462. DOI: 10.3969/j.issn.1001-5256.2023.02.033

Abstract(741)

HTML (369)

PDF (2043KB)(53)

Abstract:
Hepatic alveolar echinococcosis (HAE) is a parasitic disease caused by Echinococcus multilocularis infection and has wide distribution and great harm in China. At present, ultrasound, CT, and MRI are the main radiological examination methods for HAE, with certain limitations in preoperative diagnosi...

Research advances in immune checkpoint inhibitor-related cholangitis

Yucheng HOU, Hongqiang ZHAO, Caoer DONG, Guangdong WU, Xuan TONG, Ang LI, Qian LU, Hong CHEN, Rui TANG

2023, 39(2): 463-468. DOI: 10.3969/j.issn.1001-5256.2023.02.034

Abstract(886)

HTML (897)

PDF (1896KB)(83)

Abstract:
Immune checkpoint inhibitors (ICIs) have ushered in a new era of tumor treatment; however, immunotherapy-related adverse events are critical issues that restrict the clinical application of ICIs and have attracted wide attention. The liver is one of the target organs that is easily affected. With th...

Role of tumor-associated macrophages in cholangiocarcinoma

Pinsheng HAN, Long YANG, Tao CUI, Yamin ZHANG

2023, 39(2): 469-473. DOI: 10.3969/j.issn.1001-5256.2023.02.035

Abstract(742)

HTML (511)

PDF (2014KB)(70)

Abstract:
Cholangiocarcinoma (CCA) is a highly malignant biliary tumor with strong invasion and poor prognosis and is insensitive to radiotherapy and chemotherapy. Tumor-associated macrophage (TAM) is an important component of the tumor microenvironment. CCA cells recruit TAM into tumor tissue by releasing cy...

Pathogenesis of delayed gastric emptying after pancreaticoduodenectomy and related risk factors

Zhe WANG, Xing LYU, Jiaao YU, Xiaodong SUN, Ting LI, Guoyue LYU

2023, 39(2): 474-480. DOI: 10.3969/j.issn.1001-5256.2023.02.036

Abstract(1089)

HTML (720)

PDF (1906KB)(108)

Abstract:
Delayed gastric emptying (DGE) is a common complication after pancreaticoduodenectomy (PD). The etiology and pathogenesis of DGE have not been fully elucidated in China and globally, and the majority of patients can be cured after general symptomatic treatment. This article reviews the risk factors ...

Introduction of High-quality Articles in Foreign Journals

Genes｜Identification of liver fibrosis-related microRNAs in human primary hepatic stellate cells using high-throughput sequencing

2023, 39(2): 283-283. DOI: 10.3969/j.issn.1001-5256.2023.02.gwjpwzjj1

Abstract(556)

HTML (349)

PDF (873KB)(47)

Abstract:

Journal of Hepatology｜Risk of liver fibrosis associated with long-term methotrexate therapy may be overestimated

2023, 39(2): 407-407. DOI: 10.3969/j.issn.1001-5256.2023.02.gwjpwzjj2

Abstract(583)

HTML (355)

PDF (871KB)(61)